Tel:
Fax:
Email:
Creative Biolabs

Huntington's Disease Related Antibodies

Huntington's disease (HD), also known as "chorea", was originally reported by Waters in 1842 and termed after its systematic description by American physician George Huntington in 1872. HD is a progressive disease, and patients in the early stages of HD may suffer minor involuntary movements, mild executive function impairments, and sad mood. As the disease progresses, clinical symptoms of patients typically include involuntary convulsive movements, difficulties coordinating voluntary movements, mood swings, cognitive impairment, and other mental illnesses.

Key Factors Important Targets Related Products

Key Factors of HD

HD is an autosomal dominant disorder caused by aberrant expansion (40 or more) of DNA repeats (composed of cytosine-adenine-guanine (CAG)) toward one end of the huntingtin protein (HTT). HTT is found throughout the central nervous system and has been linked to a number of cellular activities such as protein trafficking, vesicle transport, and selective autophagy. As the number of CAG repeats rises, HTT becomes more prone to misfolding and the production of insoluble aggregates. These aggregates build up and promote cell degeneration, eventually resulting in significant shrinkage of the affected brain areas.

The pathogenic hallmarks of HD are striatal atrophy and cerebral cortex cellular degeneration. The exact function of mutant huntingtin protein (mHTT) in the pathophysiology of HD is still unknown, but research has shown that it affects HD patients in a number of ways, including autophagy dysregulation, dopaminergic imbalance, oxidative stress and mitochondrial dysfunction, unusual protein aggregation, disruption of gene transcription, loss of nutritional support, and neuroinflammation.

Figure 1 Etiology of Huntington's disease. (Jiang, et al., 2023) Fig.1 Pathogenesis of Huntington's disease.1

Important Targets Related to HD

Antibodies, as a dependable tool, are significant in HD research. Creative Biolabs has professional neuroscience and antibody R&D teams that can provide thorough and professional antibody suggestions for your HD research.

CBP/CREBBP VDAC REST HIPs
Cat. No Product Name Host Application
NAB2105185SL Mouse Anti-Human CREBBP Monoclonal Antibody (CBP5695) Monoclonal DB; ICC; IP; WB
NAB2105186SL NeuroMab™ Mouse Anti-CREBBP (CBP5696) Monoclonal IF; IHC
NAB2105187SL NeuroMab™ Mouse Anti-Human CREBBP (CBP5697) Monoclonal ELISA; IF; WB
NAB2105189SL Mouse Anti-Human CREBBP Monoclonal Antibody (CBP5698) Monoclonal ICC; IP; WB
NRP-0322-P1903 Anti-CREBBP Monoclonal Antibody (CBP8020) Monoclonal WB; IHC; ICC; IP

See all CBP/CREBBP antibodies

Cat. No Product Name Host Application
NAB2007FY665 Mouse Anti-VDAC1 Monoclonal Antibody (CBP2022) Monoclonal WB; IHC; ICC; IF
NAB2010354LS NeuroMab™ Mouse Anti-VDAC1 Monoclonal Antibody (CBP2356) Monoclonal WB; IHC-P
NRP-0422-P458 NeuroMab™ Anti-VDAC1, Clone N152B/23 (CBP8559) Monoclonal WB; IHC; ICC
NRZP-0922-ZP4706 NeuroMab™ Anti-VDAC Antibody, Clone N29361 (CBP16017) Monoclonal WB; IHC
NRZP-0423-ZP458 NeuroMab™ Anti-VDAC1 BBB Shuttle Antibody, Clone N152B/23 Monoclonal WB; IHC; ICC

See all VDAC antibodies

Cat. No Product Name Host Application
NAB-08-PZ1113 Rabbit Anti-Human REST Monoclonal Antibody (CBP1679) Monoclonal IHC-P; ICC; IF
NAB2007FY1703 Mouse Anti-REST Monoclonal Antibody (CBP6754) Monoclonal IHC; IF

See all REST antibodies

Cat. No Product Name Host Application
NAB20101997CR Mouse Anti-HIP1 Monoclonal Antibody (CBP2919) Monoclonal IHC; WB; ELISA
NAB-0720-Z6078 NeuroMab™ Rabbit Anti-HIP1 Monoclonal Antibody (CBP3246) Monoclonal ICC; IF; WB; IP
NAB-2103-P365 NeuroMab™ Mouse Anti-HIP1 Monoclonal Antibody (CBP4770) Monoclonal WB; IP; IF; IHC-P
NAB-2103-P370 NeuroMab™ Mouse Anti-HIP12 Monoclonal Antibody (CBP4775) Monoclonal WB; IP
NAB-0421-R0639 NeuroMab™ Mouse Anti-HIP7 Monoclonal Antibody (CBP6056) Monoclonal IHC; WB

See all HIPs antibodies

You may contact us directly or use the related products below to request additional information, and we will respond as soon as we can.

Reference

  1. Jiang, Andrew et al. “From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington's Disease Research.” International journal of molecular sciences vol. 24,16 13021. 21 Aug. 2023,
For Research Use Only. Not For Clinical Use.

Product
Hot Products
Fill out this form for a quote Inquiry Form Send Inquiry
webinar
Inquiry Basket
compare

Send inquiry